A new fetal RHD genotyping test: Costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales

Table 3 Additional Sensitisations (England & Wales) for Different Test Sensitivities

	Additional Sensitisations/Year ¹		Incremental Cost-Effectiveness Ratio ²
RhD NIPD sensitivity ³	Scenario 1 ⁴	Scenario 2 ⁵	Scenario 1 (£/sensitisation)	Scenario 2 (£/sensitisation)
94.8% ⁶	54	744	3,005 (235)	883 (682)
96.0%	42	573	3,863 (302)	1,146 (885)
97.0%	31	430	5,234 (409)	1,527 (1,179)
98.0%	21	283	7,727 (604)	2,320 (1,793)
98.4%	17	226	9,545 (747)	2,906 (2,244)
99.0%	10	141	16,226 (1,269)	4,658 (3,597)
99.2%	8	113	20,282 (1,586)	5,812 (4,488)
99.4%	6	85	27,043 (2,115)	7,726 (5,966)
99.7%	3	42	54,086 (4,231)	15,636 (12,075)
99.9%	1	14	162,258 (12,692)	46,908 (36,225)

¹ Assuming current serology is 100% accurate.
²Incremental cost i.e. £ sterling saved per additional sensitisation produced. Figures in brackets ( ), assumes royalty fee negotiated at £2.00 per test.
³ Sensitivity range based on values reported in literature [13, 16]
⁴ Antenatal anti-D prophylaxis directed by RhD NIPD results & postnatal anti-D by serology (1.3% risk) [2]
⁵ Postnatal anti-D prophylaxis based on RhD NIPD antenatal result (13.2% risk) [3]
⁶Meta-analysis figure for diagnostic accuracy [13]

ISSN: 1471-2393